GU005
PHASE III IGRT AND SBRT VS IGRT AND HYPOFRACTIONATED IMRT FOR LOCALIZED INTERMEDIATE RISK PROSTATE CANCER
Trial overview
| Disease | Prostate cancer treatment & diagnosis |
| Topic | GU005 |
| Description | Primary Objectives to determine whether SBRT can be shown to be superior to hypofractionated IMRT in terms of GU and GI toxicity by having fewer patients that experience a minimal important decline (MID) in urinary irritation/obstructive and bowel HRQOL. |
| Physicians | Dr. Michael I. GhilezanMD, PhD Radiation Oncologist Works at 4 centers.Dr. Larry L. KestinMD, FACR Radiation Oncologist Works at 3 centers.Dr. Kay T. MillerMD Radiation Oncologist Clarkston (Radiation oncology)Dr. Frank A. ViciniMD, FACR, FASTRO Radiation oncologist Works at 3 centers. |